Acute coronary syndromes: should women receive less antithrombotic medication than men?

N Danchin

A recent meta-analysis of all randomised trials assessing the efficacy and safety of glycoprotein IIb/IIIa agents with acute coronary syndromes showed that there was a significant interaction with sex. Explaining this difference requires an analysis of whether it has any pathophysiological basis, whether antithrombotic medications are indeed less efficacious in women in different clinical situations, and whether there are any specific reasons that may have led to the provocative results of the meta-analysis.

In a meta-analysis of all randomised trials assessing the efficacy and safety of glycoprotein IIb/IIIa agents in 31 042 patients with acute coronary syndromes, Boersma and colleagues found that, although overall these agents appeared beneficial in the populations studied, there was a significant interaction with sex. Glycoprotein IIb/IIIa reduced the risk of death or myocardial infarction by 19% in men but increased it significantly by 15% in women. The question was therefore raised of the potential beneficial or harmful effects of the use of powerful antithrombotic medications in women with acute coronary syndromes, thereby questioning the validity of everyday practice in intensive care units. Answering this question requires an analysis of whether there is any pathophysiological basis why this would be the case, whether antithrombotic medications are indeed less efficacious in women in different clinical situations, and whether there are any specific reasons that may have led to the provocative results of the meta-analysis.

DO PLATELETS AND THE HAEMOSTATIC SYSTEM REACT DIFFERENTLY IN MEN AND IN WOMEN?

There is no conclusive evidence that, in acute situations, the haemostatic system of women would be less likely to benefit from antithrombotic medications. If anything, most reports suggest increased platelet reactivity in women, with a greater sensitivity of the platelets of premenopausal women, when submitted to aggregating stimuli, which may provide a rationale for the use of potent antithrombotic medications in women. It has also been shown that the platelets of premenopausal women, when submitted to aggregating stimuli, convert a greater proportion of available glycoprotein IIb/IIIa receptors to an activated state than do the platelets of men (50–80% increase compared with men). Other coagulation factors such as factor VII may also react differently in men and in women.

ARE ANTITHROMBOTIC MEDICATIONS LESS EFFICACIOUS IN WOMEN?

In acute ST elevation myocardial infarction, the Fibrinolytic Therapy Trialists’ collaborative group meta-analysis of 58 trials of thrombolysis versus placebo showed that mortality was lower for both women and men treated with intravenous thrombolytics. In addition, the efficacy of thrombolytic agents for reopening the culprit artery was found to be similar in the GUSTO I (global utilization of streptokinase and t-PA for occluded coronary arteries I) angiographic substudy. At 90 minutes, 33.5% of men and 30.9% of women had an occluded culprit artery (TIMI (thrombolysis in myocardial infarction) grade 0 or 1), and 37.8% and 38.5%, respectively, had a fully patent artery (TIMI grade 3). Reocclusion rates were not significantly different in women (8.7%) and men (5.1%). Likewise, in the TIMI 11A trial assessing the efficacy of the low molecular weight heparin enoxaparin, administered for non-ST segment elevation acute coronary syndromes, sex did not influence the anti-Xa activity recorded after enoxaparin administration.

Things may look a bit different regarding antiplatelet agents. In the HOPE (heart outcomes prevention evaluation) trial of patients with known coronary artery disease or diabetes...
glycoprotein IIb/IIIa inhibitors would be capable of “reset-
from glycoprotein IIb/IIIa blockade than men (that is,
women (4.0%), suggesting that women derived more benefit
vessel revascularisation was similar in men (3.27%) and
in terms of death, Q wave myocardial infarction, or target
of 1215 patients undergoing percutaneous intervention (32%
(p = 0.2). In addition, recent observational data in a series
and sex at either 48 hours (p = 0.063) or one year
men. There was no statistical interaction between treatment
assigned to clopidogrel or placebo in addition to their usual
management, there was no significant interaction between
sex and clopidogrel efficacy. However, the benefit on cardiovascular death and myocardial infarction or stroke prevention for clopidogrel treated patients was less pro-
nounced in women than in men.11 Conversely, in the CREDO (clopidogrel for the reduction of events during observation)
trial, a test of the efficacy of clopidogrel in addition to aspirin
in patients undergoing elective percutaneous coronary inter-
ventions, the reduction in the primary end point (death, myocardial infarction, or stroke at one year) tended to be
greater in women (32.1%) than in men (24.5%).14
With glycoprotein IIb/IIIa receptor antagonists, there was
no reported influence of sex on the antiplatelet activity of eptifibatide in the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial (a population with non-ST segment eleva-
tion acute coronary syndromes).15 In all trials of glycoprotein IIb/IIIa blockers in the setting of percutaneous coronary interventions, the benefit appears to be virtually identical in men and in women. In a meta-analysis of the abciximab trials (EPIC (evaluation of c7E3 Fab in the prevention of ischemic complications), EPILOG (evaluation of PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade), and EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting)), which enrolled 4824 men and 1771 women undergoing percutaneous coronary interventions in various clinical settings including acute coronary syndromes, the percentage of death, myocardial infarction, or urgent revascularisation by 30 days was reduced from 11.3% to 5.8% in men compared with 12.7% to 6.5% in women.16 Similar observations were made with eptifibatide in the ESPRIT (enhanced suppression of the platelet GP IIb/IIIa receptor with Integrilin therapy) trial, in which 2064 patients under-
went elective percutaneous coronary interventions and were
receiving aspirin and a thienopyridine.17 In the whole study population, at 48 hours the composite of death, myocardial infarction, urgent target vessel revascularisation, or unplanned glycoprotein IIb/IIIa use was observed in 10.5% of women and 7.9% of men (p = 0.08), suggesting a higher risk for percutaneous coronary interventions in women. At 48 hours, eptifibatide reduced the risk of death, infarction, and urgent vessel revascularisation from 14.5% to 6.0% in women versus 9.0% to 6.8% in men. At one year, these differences persisted: 28.9% v 20.0% for women and 19.5% v 16.6% for men. There was no statistical interaction between treatment and sex at either 48 hours (p = 0.063) or one year (p = 0.2). In addition, recent observational data in a series of 1215 patients undergoing percutaneous intervention (32% with unstable angina) showed that the one month outcome in terms of death, Q wave myocardial infarction, or target vessel revascularisation was similar in men (3.27%) and women (4.0%), suggesting that women derived more benefit from glycoprotein IIb/IIIa blockade than men (that is, glycoprotein IIb/IIIa inhibitors would be capable of “reset-
ing” the risk for women at the same level as that for men).18
In contrast, the meta-analysis of all six randomised trials of glycoprotein IIb/IIIa blockers in patients with non-ST segment elevation acute coronary syndromes for whom revascularisation was not specifically recommended (PRISM (platelet receptor inhibition for ischemic syndrome management), PRISM-PLUS (platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms), PARAGON A (platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network), PARAGON B, PURSUIT, and GUSTO IV ACS (global utilization of strategies to open occluded arteries IV, acute coronary syndromes)) showed a clearly detrimental effect of glycoprotein IIb/IIIa blockade on the occurrence of death or myocardial infarction by 30 days in women. This was significantly increased by 15% compared with a reduction by 19% in men.1 Although there were important differences in baseline characteristics in men and women (women were older and more often diabetic but men more often had a previous myocardial infarction or previous myocardial revascularisation, as well as increased creatine kinase MB fraction concentrations on admission), the interaction between treatment efficacy and sex persisted after multivariate adjustment.

**REASONS FOR THE DISCREPANCY BETWEEN THE META-ANALYSIS IN ACUTE CORONARY SYNDROMES AND OTHER STUDIES: THE IMPORTANCE OF POPULATION SELECTION**

At this stage, one may conclude that glycoprotein IIb/IIIa inhibitors (and, more generally, antithrombotic medications) are at least as efficacious in women as in men in a number of clinical settings but that they had no efficacy whatsoever in the populations in the trials of acute coronary syndromes. The most likely explanation for this finding may be that the women in the trials of acute coronary syndromes were not an appropriate target for using powerful antithrombotic agents. Indeed, there is no question that women included in the percutaneous coronary intervention trials or those in the S gender (women were older and more often diabetic but men more often had a previous myocardial infarction or previous myocardial revascularisation, as well as increased creatine kinase MB fraction concentrations on admission), the interaction between treatment efficacy and sex persisted after multivariate adjustment.
women than in men. Finally, in the meta-analysis from Boersma and colleagues,\(^1\) significantly more men than women had increased troponin concentrations or underwent myocardial revascularisation by either percutaneous or surgical interventions (49% \(v\) 37%, and 42% \(v\) 31%, respectively), both probably being correlated with the presence of authentic coronary artery disease. Of note in the meta-analysis, in the population with known concentrations of troponins on admission (7002 men and 4057 women), the sex difference in treatment effect disappeared if troponin status was added to the multivariate model. In patients with increased troponin concentrations on admission, glycoprotein IIb/IIIa treatment was associated with improved outcomes for both men and women (fig 1). Interestingly, in the PURSUIT trial eptifibatide treatment was beneficial only for patients with significant coronary artery disease.\(^2\) Along the same lines, in the population of the PURSUIT trial from the USA, in which twice as many patients underwent myocardial revascularisation as in the other participating countries, the efficacy of eptifibatide was equivalent in men and women.\(^3\) Therefore, considering both the ECG and biochemical markers, as well as the coronary angiographic data, it seems highly plausible that a much higher proportion of the women than of the men in these acute coronary syndromes trials did not have true coronary artery disease. Given this possibility, it is no longer surprising that, for the whole population of women, the beneficial effect of the medications would have been obliterated by a lack of efficacy in those without coronary artery disease, who did not really need them and in whom they might have increased the bleeding risk.

**SAFETY ISSUES**

Indeed, the safety of the use of powerful antithrombotic medications is also part of the story, as the beneficial effect of the drugs in terms of efficacy may be counterbalanced by an increased risk of bleeding. In the abciximab trials during percutaneous interventions, major bleeding events occurred in 2.9% \(v\) 3.0% of women (not significant) and 2.7% \(v\) 1.3% of men (\(p < 0.01\)) treated with placebo versus abciximab, respectively. Minor bleeding occurred more often in women receiving abciximab (6.7% \(v\) 4.7%), whereas there was no difference in men (2.2% \(v\) 2.3%).\(^4\) The difference was more notable in the patients who received high dose heparin at the time of the procedure. Age, however, appeared to be the most important determinant of the risk of bleeding. Likewise, in the ESPRIT trial, major and minor bleeding was more common in women who received eptifibatide (2.4% \(v\) 0.8% and 5.5% \(v\) 2.4%, respectively), whereas the difference was much less in men (1.0% \(v\) 0.3% and 2.1% \(v\) 1.8%, respectively).\(^5\) The difference between men and women, however, was no longer significant in multivariate models including age and weight. Nearly two thirds (64%) of the bleeding complications in women occurred at the femoral access site, compared with 36% in men. In the meta-analysis from Boersma and colleagues,\(^1\) the increased risk of major bleeding was slightly higher in women (RR 2.2, 95% CI 1.6 to 2.9) than in men (RR 1.6, 95% CI 1.3 to 2.0) but there was no evidence of heterogeneity according to sex. To summarise, there is no consistent evidence that the increase in bleeding risk after glycoprotein IIb/IIIa blockade is much higher in women than in men and that it would be likely to offset the benefits of these agents in terms of efficacy.

**CONCLUSION**

From all these data, it appears that glycoprotein IIb/IIIa receptor blockers, as well as other antithrombotic medications, are likely to benefit women as much as men, provided they are targeted at the right population, namely patients with significant coronary artery disease at high risk of developing clinical complications. In such a population with acute coronary syndromes, which can be stratified by clinical, electrocardiographic, and biochemical data recorded on and within the first hours of admission, there is a large amount of evidence that the combination of the use of glycoprotein IIb/IIIa inhibitors and an invasive strategy with early angiography and myocardial revascularisation, such as recently recommended by the European Society of Cardiology, is beneficial, for both women and men.\(^2\) The meta-analysis from Boersma and colleagues,\(^3\) when read in the light of the other information available, does not contradict this statement.

**REFERENCES**

Sinus of Valsalva to right atrial fistula

The patient is a 46 year old man with hypertension who on routine physical exam was noted to have a continuous cardiac murmur. Transthoracic echocardiogram demonstrated a sinus of Valsalva fistula extending into the right atrium. A transesophageal echocardiogram (TOE) was then performed to better characterise the abnormality (see panels). The patient underwent closure of the aorto-right atrial fistula with a pericardial patch. The patient had an uneventful postoperative course and was discharged home.

Aortic cusp fistulas should be part of the differential diagnosis when a continuous cardiac murmur is auscultated.

M S Chen, H Gurm, C R Asher
asherc@ccf.org

Colour Doppler of TOE short axis view at the level of the aortic valve. Blood flow can be seen passing from the non-coronary cusp into the right atrium.

TOE short axis view at the level of the aortic valve. A defect (arrowhead) is visualised between the non-coronary cusp and the right atrium. LCC, left coronary cusp; NCC, non-coronary cusp; RA, right atrium; RCC, right coronary cusp; RV, right ventricle.

Continuous wave Doppler of TOE short axis view at the level of the aortic valve. A high velocity flow through the fistula is evident in both systole and diastole.

www.heartjn.com
Acute coronary syndromes: should women receive less antithrombotic medication than men?
N Danchin

Heart 2004 90: 363-366
doi: 10.1136/hrt.2002.003483

Updated information and services can be found at:
http://heart.bmj.com/content/90/4/363

These include:

References
This article cites 23 articles, 4 of which you can access for free at:
http://heart.bmj.com/content/90/4/363#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/